Gender differences in cocaine-induced hyperactivity and dopamine transporter trafficking to the plasma membrane.
cocaine addiction
cocaine hydrolysis
enzyme therapy
Journal
Addiction biology
ISSN: 1369-1600
Titre abrégé: Addict Biol
Pays: United States
ID NLM: 9604935
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
24
08
2022
received:
20
06
2022
accepted:
22
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
1
11
2022
Statut:
ppublish
Résumé
As well known, cocaine induces stimulant effects and dopamine transporter (DAT) trafficking to the plasma membrane of dopaminergic neurons. In the present study, we examined cocaine-induced hyperactivity along with cocaine-induced DAT trafficking and the recovery rate of the dopaminergic system in female rats in comparison with male rats, demonstrating interesting gender differences. Female rats are initially more sensitive to cocaine than male rats in terms of both the DAT trafficking and hyperactivity induced by cocaine. Particularly, intraperitoneal (i.p.) administration of 5 mg/kg cocaine induced significant hyperactivity and DAT trafficking in female rats but not in male rats. After repeated cocaine exposures (i.e., i.p. administration of 20 mg/kg cocaine every other day from Day 0 to Day 32), cocaine-induced hyperactivity in female rats gradually became a clear pattern of two phases, with the first phase of the hyperactivity lasting for only a few minutes and the second phase lasting for over an hour beginning at ~30 min, which is clearly different from that of male rats. It has also been demonstrated that the striatal DAT distribution of female rats may recover faster than that of male rats after multiple cocaine exposures. Nevertheless, despite the remarkable gender differences, our recently developed long-acting cocaine hydrolase, known as CocH5-Fc(M6), can similarly and effectively block cocaine-induced DAT trafficking and hyperactivity in both male and female rats.
Identifiants
pubmed: 36301205
doi: 10.1111/adb.13236
pmc: PMC9625146
mid: NIHMS1838391
doi:
Substances chimiques
Dopamine Plasma Membrane Transport Proteins
0
Cocaine
I5Y540LHVR
Dopamine Uptake Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13236Subventions
Organisme : NIDA NIH HHS
ID : R01 DA035552
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA056646
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA025100
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA032910
Pays : United States
Organisme : NIDA NIH HHS
ID : UH2 DA041115
Pays : United States
Organisme : NIDA NIH HHS
ID : UH3 DA041115
Pays : United States
Organisme : NIDA NIH HHS
ID : U18 DA052319
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA051079
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA013930
Pays : United States
Informations de copyright
© 2022 Society for the Study of Addiction.
Références
AAPS J. 2018 Mar 19;20(3):53
pubmed: 29556863
J Stud Alcohol. 1999 Mar;60(2):252-60
pubmed: 10091964
Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):422-7
pubmed: 26712009
AAPS J. 2017 Nov 27;20(1):3
pubmed: 29181644
Psychiatr Clin North Am. 2010 Jun;33(2):339-55
pubmed: 20385341
J Neurosci Res. 2017 Jan 2;95(1-2):136-147
pubmed: 27870394
J Pharm Biomed Anal. 2017 Feb 5;134:243-251
pubmed: 27923200
Open Pharmacol J. 2008;2(9):70-78
pubmed: 19568322
J Am Chem Soc. 2003 Mar 5;125(9):2462-74
pubmed: 12603134
J Am Chem Soc. 2008 Sep 10;130(36):12148-55
pubmed: 18710224
Biochem J. 2014 Jun 15;460(3):447-57
pubmed: 24870023
Neuroendocrinology. 1993 Jul;58(1):16-22
pubmed: 8264850
Drug Alcohol Depend. 2002 Sep 1;68(1):65-85
pubmed: 12167553
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16656-61
pubmed: 16275916
Org Biomol Chem. 2020 Mar 11;18(10):1968-1977
pubmed: 32101217
Pharmacol Rev. 2016 Apr;68(2):242-63
pubmed: 26772794
Neuropharmacology. 2005 Nov;49(6):750-8
pubmed: 16212991
Future Med Chem. 2009 Jun;1(3):515-28
pubmed: 20161378
Bioconjug Chem. 2022 Jul 20;33(7):1340-1349
pubmed: 35767675
Addict Biol. 2022 Jul;27(4):e13179
pubmed: 35754103
Chem Biol Interact. 2019 Jun 1;306:89-95
pubmed: 30986387
Pharmacol Rep. 2011;63(5):1085-92
pubmed: 22180350
Brain Res. 1995 Sep 18;692(1-2):269-72
pubmed: 8548314
Am J Psychiatry. 1999 Feb;156(2):238-45
pubmed: 9989560
Addict Biol. 2022 Jan;27(1):e13089
pubmed: 34363291
Nat Commun. 2014 Mar 18;5:3457
pubmed: 24643289
Nicotine Tob Res. 2006 Oct;8(5):627-38
pubmed: 17008190
Addiction. 1999 Sep;94(9):1413-9
pubmed: 10615725
Neuropharmacology. 2020 Oct 1;176:108251
pubmed: 32710979
Addict Behav. 2011 Apr;36(4):408-11
pubmed: 21196083
Biophys J. 2007 Nov 15;93(10):3627-39
pubmed: 17704152
J Affect Disord. 2005 Dec;89(1-3):115-23
pubmed: 16213028
Handb Clin Neurol. 2012;106:419-31
pubmed: 22608635
Biochem J. 2014 Jan 1;457(1):197-206
pubmed: 24125115
Chem Biol Interact. 2010 Sep 6;187(1-3):148-52
pubmed: 20060817
Biochemistry. 2010 Oct 26;49(42):9113-9
pubmed: 20886866
Future Med Chem. 2011 Jan;3(1):9-13
pubmed: 21428822
Psychiatr Clin North Am. 1999 Jun;22(2):241-52
pubmed: 10385931
J Addict Dis. 2003;22(4):61-74
pubmed: 14723478
AAPS J. 2020 Mar 18;22(3):62
pubmed: 32189158
Eur J Neurosci. 2019 Aug;50(4):2740-2749
pubmed: 31111573
Mol Pharmacol. 2011 Feb;79(2):290-7
pubmed: 20971807
Neuropsychopharmacology. 2005 May;30(5):1006-18
pubmed: 15785780
Future Med Chem. 2012 Feb;4(2):125-8
pubmed: 22300091
ACS Chem Biol. 2016 Aug 19;11(8):2186-94
pubmed: 27224254
Psychiatry Res. 2013 Jan 30;211(1):72-7
pubmed: 23036826